NDAORALTABLET, DELAYED RELEASE
Approved
Aug 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
12
Data completeness
6/8 — Strong
ACIPHEX (rabeprazole sodium) by Viatris (2) is (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine h 2 -receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric h, katpase at the secretory surface of the gastric parietal cell. Approved for gastroesophageal reflux disease, heartburn, helicobacter pylori infection and 1 more indications. First approved in 1999.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACIPHEX (rabeprazole sodium) is an oral delayed-release tablet proton-pump inhibitor (PPI) approved since 1999 for treating daytime and nighttime heartburn and other symptoms of gastroesophageal reflux disease (GERD) in adults for up to 4 weeks, and in adolescents 12 years and older for up to 8 weeks. It works by inhibiting the gastric H+/K+-ATPase enzyme at the parietal cell secretory surface, blocking the final step of gastric acid secretion. Rabeprazole is chemically activated in the acidic gastric environment and accumulates in parietal cells where it is converted to an active sulfenamide form. ACIPHEX remains a standard therapy in the PPI class for short-term GERD management alongside multiple generic and branded competitors.
$0.0BPart D
Mechanism of Action
(substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H 2 -receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H, KATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as…
Indications (4)
Worked on ACIPHEX at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.